AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of pain and other conditions. It offers NanoTab, a tablet for oral transmucosal administration. The Company also provides Sufentanil NanoTab PCA system, a sublingual patient-controlled analgesia system with a drug/device combination product candidate for the management of acute post-operative pain in the hospital settings; Sufentanil NanoTab BTP management systems for the treatment option for patients with cancer pain; and Sufentanil/Triazolam NanoTab, which provides analgesia and sedation for minor outpatient procedures. It serves patients, physicians, regulators, and payers. 
Company Growth (employees)
Redwood City, US
Size (employees)
39 (est)
AcelRx Pharmaceuticals was founded in 2005 and is headquartered in Redwood City, US

AcelRx Pharmaceuticals Office Locations

AcelRx Pharmaceuticals has an office in Redwood City
Redwood City, US (HQ)
351 Galveston Dr
Show all (1)

AcelRx Pharmaceuticals Financials and Metrics

AcelRx Pharmaceuticals Financials

AcelRx Pharmaceuticals's revenue was reported to be $17.4 m in FY, 2016

Revenue (Q2, 2017)

2.7 m

Gross profit (Q2, 2017)

(884 k)

Gross profit margin (Q2, 2017), %


Net income (Q2, 2017)

(13.1 m)

EBIT (Q2, 2017)

(9.9 m)

Market capitalization (22-Dec-2017)

96.2 m

Cash (30-Jun-2017)

62.1 m


49 m
AcelRx Pharmaceuticals's current market capitalization is $96.2 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016


29.5 m5.2 m19.3 m17.4 m

Revenue growth, %


Cost of goods sold

1.8 m12.3 m

Gross profit

17.5 m5 m
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


15.4 m3 m4.5 m3.4 m3.1 m2.7 m

Cost of goods sold

3.6 m3 m2.6 m4.1 m3.5 m

Gross profit

(574 k)1.6 m787 k(1 m)(884 k)

Gross profit Margin, %

USDFY, 2013FY, 2014FY, 2015FY, 2016


88.4 m60 m107.9 m80.3 m

Accounts Receivable

3.3 m5.8 m


897 k948 k466 k2.2 m

Current Assets

104.6 m76.3 m118.9 m89.1 m
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


95 m105.4 m97.8 m92.5 m72.3 m62.1 m

Accounts Receivable

17.4 m3.2 m4.2 m2 m2.7 m2.1 m


910 k1.3 m1.4 m1.9 m1.6 m

Current Assets

122.6 m112.8 m105.6 m96.9 m78 m66.8 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(23.4 m)(33.4 m)(24.4 m)(43.2 m)

Depreciation and Amortization

593 k866 k2 m2.1 m

Accounts Receivable

(3.3 m)(2.5 m)


(466 k)(1.7 m)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

5.1 m(11 m)(11.1 m)(11.4 m)(15.6 m)

Accounts Receivable

17.4 m3.2 m4.2 m2 m2.7 m


910 k1.3 m1.4 m1.9 m

Accounts Payable

1.2 m2.2 m2.8 m2.9 m1.6 m1.7 m3.6 m2.9 m1.4 m1.7 m
Y, 2017


-4.9 x
Show all financial metrics

AcelRx Pharmaceuticals Operating Metrics

FY, 2016

Phase III Trials


Patents (US)


Patents (foreign)

Show all operating metrics

AcelRx Pharmaceuticals Market Value History

AcelRx Pharmaceuticals's Web-traffic and Trends

AcelRx Pharmaceuticals Company Life and Culture

You may also be interested in